Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 145Head and Neck Neoplasms 79Squamous Cell Carcinoma of Head and Neck 68Rectal Neoplasms 46Colonic Neoplasms 42Carcinoma, Non-Small-Cell Lung 39Neoplasm Metastasis 35Neoplasms 25Carcinoma, Squamous Cell 20Pancreatic Neoplasms 17Lung Neoplasms 16Esophageal Neoplasms 15Stomach Neoplasms 12Recurrence 11Laryngeal Neoplasms 11Mouth Neoplasms 10Oropharyngeal Neoplasms 8Esophageal Squamous Cell Carcinoma 8Breast Neoplasms 8Adenocarcinoma Of Esophagus 8Tongue Neoplasms 7Uterine Cervical Neoplasms 6Nasopharyngeal Carcinoma 6Laryngeal Diseases 6Hypopharyngeal Neoplasms 6Colorectal Cancer Metastatic 6Carcinoma 6Adenocarcinoma of Lung 6Salivary Gland Neoplasms 5Cholangiocarcinoma 4

Interventions

relatlimab 2linrodostat 2Nivolumab 2Ipilimumab 2Vorinostat 1Trastuzumab 1IFL protocol 1Gemcitabine 1Dasatinib 1Cetuximab 1BMS-813160 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Advanced Cancer × Cetuximab × Clear all
NCT00698841 2015-12-24

Study to Evaluate the Effect of Cetuximab on Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors

Eli Lilly and Company

Phase 2 Completed
79 enrolled 7 charts

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡